Table 3: Frequencies of participants' genotypes among endometrial cancer cases and population-based controls who returned urine and saliva samples.
|
SNP (N missing) Genotype |
Number of individuals (percentage) |
Cases (N = 480) |
Controls (N = 513) |
P-value* |
|
rs352038 (6) CC |
1 (0.1) |
1 (0.2) |
0 (0.0) |
0.39 |
|
CT |
28 (2.8) |
16 (3.3) |
12 (2.4) |
|
|
TT |
958 (97.1) |
463 (96.5) |
495 (97.6) |
|
|
rs2234693 CC |
127 (12.8) |
68 (14.2) |
59 (11.5) |
0.29 |
|
CT |
416 (41.9) |
205 (42.7) |
211 (41.1) |
|
|
TT |
450 (45.3) |
207 (43.1) |
243 (47.4) |
|
|
rs9340799 AA |
400 (40.3) |
194 (40.4) |
206 (40.2) |
0.9 |
|
AG |
461 (46.4) |
220 (45.8) |
241 (47.0) |
|
|
GG |
132 (13.3) |
66 (13.8) |
66 (12.9) |
|
|
rs3020314 CC |
106 (10.7) |
50 (10.4) |
56 (10.9) |
0.66 |
|
CT |
461 (46.4) |
230 (47.9) |
231 (45.0) |
|
|
TT |
426 (42.9) |
200 (41.7) |
226 (44.1) |
|
|
rs1255998 CC |
795 (80.1) |
380 (79.2) |
415 (80.9) |
0.18 |
|
CG |
181 (18.2) |
88 (18.3) |
93 (18.1) |
|
|
GG |
17 (1.7) |
12 (2.5) |
5 (1.0) |
|
|
rs944050 AA |
923 (93.0) |
451 (94.0) |
472 (92.0) |
0.19 |
|
AG |
69 (6.9) |
28 (5.8) |
41 (8.0) |
|
|
GG |
1 (0.1) |
1 (0.2) |
0 (0.0) |
|
|
rs4775936 (12) CC |
301 (30.7) |
139 (29.3) |
162 (32.0) |
0.48 |
|
CT |
469 (47.8) |
236 (49.8) |
233 (46.0) |
|
|
TT |
211 (21.5) |
99 (20.9) |
112 (22.1) |
|
|
rs28366003 (6) AA |
890 (90.2) |
434 (91.0) |
456 (89.4) |
0.5 |
|
AG |
94 (9.5) |
41 (8.6) |
53 (10.4) |
|
|
GG |
3 (0.3) |
2 (0.4) |
1 (0.2) |
|
|
rs3918249 (9) CC |
123 (12.5) |
68 (14.3) |
55 (10.8) |
0.16 |
|
CT |
445 (45.2) |
219 (45.9) |
226 (44.6) |
|
|
TT |
416 (42.3) |
190 (39.8) |
226 (44.6) |
|
|
rs12011793 CC |
7 (0.7) |
5 (1.0) |
2 (0.4) |
0.19 |
|
CT |
124 (12.5) |
67 (14.0) |
57 (11.1) |
|
|
TT |
862 (86.8) |
408 (85.0) |
454 (88.5) |
|
|
rs12011518 GG |
870 (87.6) |
414 (86.2) |
456 (88.9) |
0.23 |
|
GT |
122 (12.3) |
65 (13.5) |
57 (11.1) |
|
|
TT |
1 (0.1) |
1 (0.2) |
0 (0.0) |
|
|
ESR1 Haplotype CAC |
13 (1.3) |
11 (2.3) |
2 (0.4) |
0.01 |
|
CAT |
108 (10.9) |
56 (11.7) |
52 (10.1) |
0.48 |
|
CGC |
98 (9.9) |
49 (10.2) |
49 (9.6) |
0.75 |
|
CGT |
404 (40.7) |
198 (41.2) |
206 (40.2) |
0.75 |
|
TAC |
486 (48.9) |
238 (49.6) |
248 (48.3) |
0.7 |
|
TAT |
492 (49.5) |
234 (48.8) |
258 (50.3) |
0.66 |
|
TGC |
24 (2.4) |
12 (2.5) |
12 (2.3) |
0.99 |
|
TGT |
144 (14.5) |
63 (13.1) |
81 (15.8) |
0.24 |
|
ESR2 Haplotype CA |
976 (98.3) |
468 (97.5) |
508 (99.0) |
0.09 |
|
GA |
133 (13.4) |
73 (15.2) |
60 (11.7) |
0.11 |
|
GG |
70 (7.1) |
29 (6.0) |
41 (8.0) |
0.26 |
|
AR Haplotype CG |
13 (1.3) |
10 (2.1) |
3 (0.6) |
0.05 |
|
CT |
122 (12.3) |
65 (13.5) |
57 (11.1) |
0.25 |
|
TG |
986 (99.3) |
475 (99.0) |
511 (99.6) |
0.27 |
|
TT |
1 (0.1) |
1 (0.2) |
0 (0.0) |
0.48 |
ESR1 = estrogen receptor 1; ESR2 = estrogen receptor 2; AR = androgen receptor; *Fisher’s Exact Test.